Commercial Samples and the Eighty Percent Shelf-Life Rule

1. Key takeaways

Nicaragua requires samples of the product under registration in commercial secondary packaging, with a remaining shelf life of not less than 80 percent of the labelled life (Chapter 6, item 13 of NTON 24001:2023). Two categories are exempt: medical equipment for hospital use and in vitro diagnostic devices requiring special storage conditions. Under item 14, DDM periodically publishes the list of products that must be submitted for testing together with the quantity of samples required, and the samples used for laboratory analysis are independent of those submitted to DDM. Sample delivery is the exception to the otherwise fully online procedure and has its own three working day window.

• The eighty percent figure is a floor on remaining shelf life at the time of delivery, which requires planning backwards from the arrival date.
• Only two exemptions exist, and both are defined by product type and storage conditions rather than by company size or consignment value.
• Sample quantities are not fixed; they follow the list that DDM publishes periodically.
• Two separate sets of samples exist: those filed with DDM and those taken by the laboratory at first-import analysis.
• Physical samples must match the label artwork, the application form and the CLV.

2. Legal basis

The provisions below cover the shelf-life requirement, the two exemptions, the sample list and the procedural exception for physical delivery, together with the labelling consistency rule that applies to the samples themselves.

3. Expert insights

Insight 1: the eighty percent figure is a floor on remaining life. The text reads con vencimiento mínimo equivalente al 80% de su vida útil, which means that production batches and transport times must be planned backwards from the delivery date. Short-dated products, including some IVD reagents, need batch allocation calculated from the expected arrival date; otherwise the product is already below eighty percent when it lands.

Insight 2: there are only two exemptions, and they are drafted specifically: Excepto equipos médicos de uso hospitalario y dispositivos médicos de diagnóstico in vitro que requieran condiciones especiales de almacenamiento. Large hospital equipment and IVDs needing special storage conditions are exempt, and everything else is not. The judgement turns on product format and storage conditions, not on the size of the company or the value of the shipment.

Insight 3: the sample quantity is not a fixed number. Item 14 leaves it to DDM to publicar de manera periódica el listado de productos que se someterán a análisis y la cantidad de muestras requerida. Before preparing samples, the current list must be retrieved; the quantity used last time cannot simply be carried forward.

Insight 4: the two sets of samples are unrelated. The closing sentence of item 14 states that La cantidad de muestras para análisis que se presentan en laboratorio son independientes a las que se deben presentar en la Dirección de Dispositivos médicos. The samples filed with DDM at registration and the samples taken by the laboratory at first-import analysis are two different sets with two different quantities.

Insight 5: sample delivery is the exception to the fully online process and is timed separately. Article 5(d) of Annex I lists sample delivery as the exception to online handling, and Article 11, item 9, allows three working days after preliminary review to deliver them. That window does not overlap with the evaluation clock, and it is a segment frequently omitted from project schedules.

Insight 6: the physical sample and the label artwork must agree. Sub-item k of item 12 requires the labelling and packaging, in original or as artwork, to conform to the application form and the CLV. If the sample does not match the artwork filed, the discrepancy becomes a new non-conformity at the evaluation stage rather than being caught at preliminary review.

4. Practical recommendations

• Plan production batches and transport backwards from the arrival date, so that the remaining shelf life is not below eighty percent of the labelled life.
• Assess the two exemptions first, hospital medical equipment and IVDs needing special storage, rather than deciding on the basis of value or volume.
• Retrieve the currently published list of products subject to testing and the sample quantities before delivery, and do not reuse last year’s figures.
• Keep the two sample sets separate: the registration samples filed with DDM and the samples taken by the laboratory at first-import analysis.
• Have the samples ready before preliminary review is passed, reserving the three working day delivery window.
• Reconcile the physical sample with the label artwork, the application form and the CLV word for word.

5. Verification checklist

• □ Production batches have been planned backwards from the arrival date, with remaining shelf life not below eighty percent of the labelled life
• □ Whether the product falls within either exemption has been assessed, and the reasoning retained on file
• □ The currently published list of products subject to testing and the sample quantities have been retrieved
• □ The samples filed with DDM and those for laboratory analysis are kept as two separate quantities
• □ Samples are ready before preliminary review is passed, with the three working day window reserved
• □ The physical sample matches the label artwork, application form and CLV word for word

Related reading: [The fourteen registration items in full: Chapter 6 item by item](/nicaragua-medical-device-registration/fourteen-registration-requirements/) | [What the official application form asks for: information on five parties](/nicaragua-medical-device-registration/official-application-form-five-parties/) | [First-import analysis and the release letter: the ninety-day batch rule and destruction obligations](/nicaragua-medical-device-registration/first-import-analysis-and-release-letter/)

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com